BR102021016375B1 - Processo de produção de nanopartículas biogênicas de prata, nanopartículas biogênicas de prata e usos das nanopartículas biogênicas de prata - Google Patents
Processo de produção de nanopartículas biogênicas de prata, nanopartículas biogênicas de prata e usos das nanopartículas biogênicas de prata Download PDFInfo
- Publication number
- BR102021016375B1 BR102021016375B1 BR102021016375-5A BR102021016375A BR102021016375B1 BR 102021016375 B1 BR102021016375 B1 BR 102021016375B1 BR 102021016375 A BR102021016375 A BR 102021016375A BR 102021016375 B1 BR102021016375 B1 BR 102021016375B1
- Authority
- BR
- Brazil
- Prior art keywords
- solution
- biogenic
- silver nanoparticles
- silver
- nanoparticles
- Prior art date
Links
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 title claims abstract description 99
- 230000000035 biogenic effect Effects 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims abstract description 81
- 230000008569 process Effects 0.000 title claims abstract description 67
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims abstract description 64
- 239000000284 extract Substances 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 229910052709 silver Inorganic materials 0.000 claims abstract description 23
- 239000004332 silver Substances 0.000 claims abstract description 23
- 241001193391 Trichilia catigua Species 0.000 claims abstract description 20
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 20
- 229910001961 silver nitrate Inorganic materials 0.000 claims abstract description 17
- 238000009472 formulation Methods 0.000 claims abstract description 16
- 244000005700 microbiome Species 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 89
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 230000000840 anti-viral effect Effects 0.000 claims description 9
- 239000004599 antimicrobial Substances 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 8
- 229920001992 poloxamer 407 Polymers 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 7
- 229920001993 poloxamer 188 Polymers 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- 239000004753 textile Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000011012 sanitization Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 238000001471 micro-filtration Methods 0.000 claims description 2
- 241000004176 Alphacoronavirus Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- -1 pharmaceutical Substances 0.000 abstract description 3
- 239000002105 nanoparticle Substances 0.000 description 54
- 238000012360 testing method Methods 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 239000000499 gel Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 241000711573 Coronaviridae Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 230000003253 viricidal effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 229960003600 silver sulfadiazine Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229910017745 AgNP Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 241001349574 Diplocyclos palmatus Species 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 241001149959 Fusarium sp. Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000088436 Neurospora sp. Species 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000228168 Penicillium sp. Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241001158887 Piriformospora sp. Species 0.000 description 1
- 241001021986 Pisolithus sp. Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001640220 Solenostemma argel Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 241001207473 Sporisorium sp. Species 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000002338 electrophoretic light scattering Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102021016375-5A BR102021016375B1 (pt) | 2021-08-18 | 2021-08-18 | Processo de produção de nanopartículas biogênicas de prata, nanopartículas biogênicas de prata e usos das nanopartículas biogênicas de prata |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102021016375-5A BR102021016375B1 (pt) | 2021-08-18 | 2021-08-18 | Processo de produção de nanopartículas biogênicas de prata, nanopartículas biogênicas de prata e usos das nanopartículas biogênicas de prata |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR102021016375A2 BR102021016375A2 (https=) | 2021-11-30 |
| BR102021016375B1 true BR102021016375B1 (pt) | 2022-11-08 |
Family
ID=84178987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR102021016375-5A BR102021016375B1 (pt) | 2021-08-18 | 2021-08-18 | Processo de produção de nanopartículas biogênicas de prata, nanopartículas biogênicas de prata e usos das nanopartículas biogênicas de prata |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR102021016375B1 (https=) |
-
2021
- 2021-08-18 BR BR102021016375-5A patent/BR102021016375B1/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR102021016375A2 (https=) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cui et al. | The specific antibacterial effect of the Salvia oil nanoliposomes against Staphylococcus aureus biofilms on milk container | |
| Lima et al. | Antimicrobial effect of anacardic acid–loaded zein nanoparticles loaded on Streptococcus mutans biofilms | |
| Ferreira et al. | Essential oils encapsulated in zeolite structures as delivery systems (EODS): an overview | |
| WO2018024087A1 (zh) | 空气净化消毒剂及制备方法 | |
| JP2016530222A (ja) | 広い範囲の微生物の除去のための官能基及び表面に吸着された柑橘類抽出物で改質されたナノ粒子の二酸化チタンナノ材料 | |
| Zheng et al. | Utilization of nanoemulsion to enhance antibacterial capacity of Zanthoxylum bungeanum pericarp essential oils against foodborne pathogenic bacteria | |
| Elian et al. | Biobased polymer resources and essential oils: a green combination for antibacterial applications | |
| Nystedt et al. | Neutral natural deep eutectic solvents as anti-biofilm agents | |
| JP7054325B2 (ja) | 抗菌及び抗ウイルス用組成物 | |
| CN103598225B (zh) | 防治水稻病害的生物杀菌剂 | |
| da Silva et al. | Synthesis, characterization and antibiofilm/antimicrobial activity of nanoemulsions containing Tetragastris catuaba (Burseraceae) essential oil against disease-causing pathogens | |
| Jose et al. | Activity of clove oil and chitosan nanoparticles incorporated PVA nanocomposite against Pythium aphanidermatum | |
| Su et al. | Antibacterial property and mechanism of a novel Pu-erh tea nanofibrous membrane | |
| Hamid et al. | Photochemical, antioxidant and antibacterial activities of some extracts of water hyacinth (Eichhornia crassipes) leaves | |
| US20190200616A1 (en) | Preparation method and use of an atomic-state fluid iodine and its derived nano-iodine | |
| Kenawy et al. | Assessing the Bactericidal Effectiveness of Clove Oil Nanoemulsion‐Loaded Polycaprolactone Nanofibers for Eco‐Friendly and Endurable Food Packaging | |
| WO2013082687A1 (pt) | Composição microbicida e processo de obtenção da mesma | |
| BR102021016375B1 (pt) | Processo de produção de nanopartículas biogênicas de prata, nanopartículas biogênicas de prata e usos das nanopartículas biogênicas de prata | |
| Nomura-Contreras et al. | FreshPack: Harnessing hydrophobic fibers loaded with oregano essential oil and carvacrol for easy and effective food preservation | |
| CN105997561A (zh) | 一种酪蛋白-百里香精油脂质体抗菌剂的制备方法和用途 | |
| JP7432218B2 (ja) | サクラソウ科植物の抽出物の用途 | |
| CN105999039B (zh) | 一种酪蛋白-豆蔻精油脂质体抗菌剂的制备方法和用途 | |
| Parviz et al. | Tea Tree (Melaleuca alternifolia (Maiden & Betche) Cheel) Oil an important medicinal essential oil | |
| CN110063908A (zh) | 纳米乳液型漱口水及其制备方法和应用方法 | |
| Santoso et al. | Antibacterial activity and composition of hand sanitizer from white turmeric extract as a prevention of Covid-19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03B | Publication of an application: publication anticipated [chapter 3.2 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2021, OBSERVADAS AS CONDICOES LEGAIS |